In this retrospective multi-center cohort study, we aimed to evaluate the therapeutic benefit in migraine patients who switched from prophylactic treatment with a CGRP-R-mAb to a CGRP-mAb due to non-response. This evidence concerns the gene CALCRL and migraine disorder.